-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Tenaya Highlights Urgent Need For Disease-Modifying Approaches In Pediatric MYBPC3-Associated HCM Based On MyClimb Interim Findings

Benzinga·09/02/2025 07:42:02
Listen to the news
  • Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants
  • 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics
  • Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes